Form 4: Organon Executive's RSU Vesting Boosts Stock Holdings

Juliana Drinane, Interim Head of Manufacturing & Supply at Organon & Co., increased her direct beneficial ownership of common stock following the vesting of restricted stock units.

Summary

• Juliana Drinane, Interim Head of Manufacturing & Supply at Organon & Co., reported changes in her beneficial ownership of company stock.
• On November 7, 2025, 3,626 Restricted Stock Units (RSUs) vested, converting into an equal number of common stock shares.
• These RSUs were part of an original grant of 10,876 units made on November 7, 2023, which vest one-third annually, with the final vesting scheduled for November 7, 2026.
• Following the vesting, 3,626 shares of common stock were acquired at a price of $0.
• Additionally, 1,242 shares of common stock were acquired at a price of $6.71 under transaction code 'F', which typically relates to tax withholding but is marked as an acquisition in this filing.
• After these transactions, Drinane directly beneficially owns 19,658.703 shares of Organon & Co. common stock.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event (RSU vesting) which increases the executive's direct ownership, aligning interests with shareholders. It does not contain any unexpected positive or negative news regarding company operations or financial performance.

Positives

• Increased direct beneficial ownership of Organon & Co. common stock by a key executive, Juliana Drinane.
• The vesting of RSUs indicates the executive is receiving compensation tied to company performance and continued employment.
• The executive's increased stake in the company further aligns her interests with those of shareholders.

Negatives

• No explicit negatives identified in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The filing indicates that the remaining one-third of the original 10,876 RSU grant will vest on November 7, 2026, representing a future increase in the executive's direct beneficial ownership of common stock, assuming continued employment.

Industry Context

This Form 4 filing reflects routine executive compensation practices within publicly traded companies, where Restricted Stock Units are a common form of equity incentive designed to align executive interests with long-term shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule is a standard practice in executive compensation across various industries, including pharmaceuticals and healthcare, to retain talent and incentivize long-term performance.
• Companies like Pfizer, Merck, and Johnson & Johnson commonly utilize similar equity compensation structures for their executives, aligning with the general industry norms for executive incentive plans seen in this filing.

Related Party Transactions

• The RSU vesting represents a standard compensation transaction between the company and an executive, which is a form of related party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to higher direct stock ownership.
• Management: Juliana Drinane's compensation package is being realized, reinforcing her stake in the company.

Next Steps

• The final tranche of the 10,876 RSUs granted on November 7, 2023, is expected to vest on November 7, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU vesting) and does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The increase in executive ownership is a positive for alignment but is an expected part of compensation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for a buy or sell decision.

Keywords

Organon & Co., OGN, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU vesting, Executive compensation, Beneficial ownership, Juliana Drinane